[Chronic cystitis: how to prolong the relapse-free period?]

Area of Science:

• Urology
• Infectious Diseases
• Pharmacology

Background:

• Chronic cystitis is a prevalent form of urinary tract infections (UTIs).
• Current international guidelines inadequately address the management of chronic cystitis.
• There is a need for effective therapeutic strategies for chronic cystitis.

Purpose of the Study:

• To evaluate the long-term efficacy of Superlymph rectal suppositories in combination with standard antibiotic therapy for chronic cystitis.
• To compare different dosages and durations of Superlymph treatment for chronic cystitis management.

Main Methods:

• A prospective, multicenter, randomized controlled study involving 91 patients with chronic cystitis.
• Three groups were established: standard antibiotic therapy alone (Group 1), standard therapy plus 25 IU Superlymph for 10 days (Group 2), and standard therapy plus 10 IU Superlymph for 20 days (Group 3).
• Standard therapy included fosfomycin trometamol and furazidin. Patients were followed up for 6 months post-treatment.

Main Results:

• After 6 months, 70.4% of patients in the 10 IU Superlymph group (Group 3) remained relapse-free, compared to 44.4% in the 25 IU group (Group 2) and 39.3% in the standard therapy group (Group 1).
• The relapse-free period was significantly longer in the Superlymph groups, averaging 123.5 days in Group 3.
• The differences in recurrence rates between the groups were statistically significant (p<0.001).

Conclusions:

• Combined etiologic and pathogenetic therapy, particularly with 10 IU Superlymph for 20 days, significantly reduces chronic cystitis recurrences and extends the relapse-free period.
• Superlymph rectal suppositories represent a promising adjunctive treatment for chronic cystitis.
• Long-term symptom absence was achieved in 70.4% of patients receiving the optimal Superlymph regimen.